Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 5
Submit an article Journal homepage
744
Views
47
CrossRef citations to date
0
Altmetric
Reviews

VEGF inhibitors for the treatment of neovascular age-related macular degeneration

Mark Rami Barakat Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA +1 216-444-6702; +1 216 445 2226; [email protected]
, MD &
PK Kaiser Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA +1 216-444-6702; +1 216 445 2226; [email protected]
Pages 637-646 | Published online: 24 Apr 2009

Bibliography

  • Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72
  • Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36
  • Ruiter DJ, Schlingemann RO, Westphal JR, et al. Angiogenesis in wound healing and tumor metastasis. Behring Inst Mitt 1993;92:258-72
  • Ferrara N, Chen H, Davis-Smyth T, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998;4:336-40
  • Yano K, Brown LF, Detmar M. Control of hair-growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 2001;107:409-17
  • Kiefer FN, Neysari S, Humar R, et al. Hypertension and angiogenesis. Curr Pharm Des 2003;9:1733-44
  • Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-14
  • Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64
  • Leung DW, Cachianes G, Kuang WJ, et al. Vascular endotherlial growth factor is a secreted angiogneic mitogen. Science 1989;246:1306-9
  • Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42
  • Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998;95:11709-14
  • Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7:186-91
  • Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996;80:363-6
  • Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-34
  • Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-62
  • Ruckman J, Green LS, Beeson J, et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:20556-67
  • Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-52
  • Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
  • Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46
  • Kim KJ, Li B, Houck K, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7:53-64
  • Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-81
  • Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-53
  • Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-44
  • Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J. Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 2003;44:2141-6
  • Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33
  • Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
  • Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44
  • Lucentis® (ranibizumab injection) prescribing information. South San Francisco, California: Genentech, Inc.; 2008
  • Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145:239-48
  • Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacisumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-47
  • Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5
  • Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003;9:129-34
  • Sawada O, Kawamura H, Kakinoki M, et al. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007;125(10):1363-6
  • Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146(4):508-12
  • Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 1755;115(10):1750-5
  • Comparison of Age-Related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial. [ClinicalTrials.gov identifier: NCT00593450]. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00593450 [Last accessed 17 Dec 2008]
  • Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 2004;4:S81-5
  • Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003;9:47-52
  • VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeting. Regeneron.com. Available from: http://newsroom.regeneron.com/phoenix.zhtml?c=214847&p=irol-newsArticle&ID=1202860&highlight [Last accessed 17 Dec 2008]
  • Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003;9:210-6
  • Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.[see comment]. Nature 2008;452(7187):591-7
  • Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13(3):225-34
  • Brucker A. Small interfering RNA (CAND5) for the treatment of subfoveal choroidal neovascularization due to age-related macular degeneration. Combined Retina Society/Gonin Society Meeting; 2006 Oct 15–20; Cape Town
  • Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (COBALT). [ClinicalTrials.gov identifier: NCT00499590]. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00499590 [Last accessed 17 Dec 2008]
  • A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) [ClinicalTrials.gov identifier: NCT00363714]. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00363714 [Last accessed 17 Dec 2008]
  • A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration [ClinicalTrials.gov identifier: NCT00395057]. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00395057 [Last accessed 17 Dec 2008]
  • Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. [see comment]. N Engl J Med 2002;347(7):472-80
  • Nishida T, Shirao K, Sawaki A, et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 2008;13(3):244-51
  • George S. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Curr Oncol Rep 2007;9(4):323-7
  • Maier P, Unsoeld AS, Junnker B, et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol 2005;243(6):593-600
  • Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Mac ular Degeneration (AMD) (ADVANCE) [ClinicalTrials.gov identifier: NCT00138632]. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00138632 [Last accessed 17 Dec 2008]
  • A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD [ClinicalTrials.gov identifier: NCT00612456]. ClinicalTrials.gov. Available from: http://clinicaltrials. gov/ct2/show/NCT00612456 [Last accessed 17 Dec 2008]
  • Chen ZZ, Mak C, Renick J, et al. A dual VEGFR/JAK2 kinase inhibitor suitable for topical delivery inhibits choroid neovascularization in mice [abstract no. E-1469]. Invest Ophthalmol Vis Sci 2007;48(5). Available from: http://abstracts.iovs.org/cgi/content/abstract/48/5/1469 [Last accessed 17 Dec 2008]
  • Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD [ClinicalTrials.gov identifier: NCT00509548]. ClinicalTrials.gov. Available from: http://clinicaltrials. gov/ct2/show/NCT00509548 [Last accessed 17 Dec 2008]
  • A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration [ClinicalTrials.gov identifier: NCT00090532]. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ ct2/show/NCT00090532 [Last accessed 17 Dec 2008]
  • Bingaman DP, Gu X, Landers RA, et al. AL-39324 is more potent and efficacious against ocular NV vs. other RTKi's [abstract no. E-1747]. Invest Ophthalmol Vis Sci 2007;48(5). Available from: http://abstracts.iovs.org/cgi/content/abstract/48/5/1747 [Last accessed 17 Dec 2008]
  • Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transpl Proc 2003;35(3 Suppl):7S-14S
  • Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8(2):128-35
  • Kleinman DM, Kim DD, Nivaggioli T, et al. Sirolimus inhibits VEGF-induced microvascular hyperpermeability [abstract no. E-1422]. Invest Ophthalmol Vis Sci 2007;48(5). Available from: http://abstracts.iovs.org/cgi/content/abstract/48/5/1422 [Last accessed 17 Dec 2008]
  • Dejneka NS, Kuroki AM, Fosnot J, et al. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004;10:964-72
  • Merkel S, Mogilevskaja N, Mengel M, et al. Side effects of sirolimus. Transpl Proc 2006;38(3):714-5
  • Morath C, Schwenger V, Ksoll-Rudek D, et al. Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors. Transpl Proc 2007;39(1):99-102
  • Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007;83(9):1162-8
  • Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration [ClinicalTrials.gov identifier: NCT00712491]. ClinicalTrials.gov. Available from: http://clinicaltrials. gov/ct2/show/NCT00712491 [Last accessed 17 Dec 2008]
  • Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration (EMERALD) [ClinicalTrials.gov identifier: NCT00766337]. ClinicalTrials.gov. Available from: http://clinicaltrials. gov/ct2/show/NCT00766337 [Last accessed 17 Dec 2008]
  • Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83
  • Lalwani G. All About PrONTO: Study Yielded Good Results in AMD With Treatment Guided by OCT. www.retinatoday.com. http://www.retinatoday.com/Html%20Pages/0507/0507_cme.html [Last accessed 18/12/08]
  • Guttman C. Intravitreal ranibizumab therapy safe, well tolerated, study shows.Available from: www.modernmedicine.com. Available from: http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Intravitreal-ranibizumab-therapy-safe-well-tolerat/ArticleStandard/Article/detail/566351 [Last accessed 29 Dec 2008]
  • Steinbrook R. The price of sight – ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355(14):1409-12
  • Raftery J, Clegg A, Jone J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modeling cost effectiveness. Br J Ophthalmol 2007;91:1244-6
  • Fletcher EC, Lade RJ, Adewoyin T, Chong NV. Computerized model of cost-utility analysis for treatment of age-related macular degeneration. Ophthalmology 2008;115:2192-8
  • Swaroop A, Branham KE, Chen W, Abecasis G. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum Mol Genet 2007;16(Rev2):R174-82
  • Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 2008;115(6):1019-25

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.